Last reviewed · How we verify

NCT05348629

Efficacy and Safety of Covid-19 Vaccine in Cardiac Patients

Status unknown Last updated 27 April 2022
What this trial tests

trial in COVID-19 Vaccine in 50 participants. Status unknown.

Timeline
1 June 2022
Primary endpoint
1 June 2022
1 September 2023

Quick facts

Lead sponsorMina sobhi said fam
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date1 June 2022
Primary completion1 June 2022
Estimated completion1 September 2023
Sites2 locations across Egypt

Conditions studied

Sponsor

Mina sobhi said fam

Who can join

Adults 18 to 80, any sex, with COVID-19 Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy and safety of covid-19 vaccine in Cardiac patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COVID-19 Vaccine

Currently open trials in the same condition.

Other Mina sobhi said fam trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05348629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing